Control of hepatitis C virus replication in mouse liver-derived cells by MAVS-dependent production of type I and type III interferons

Journal of Virology

Volumn 89, Issue 7, 2015, Pages 3833-3845

  Anggakusuma, ^a   Frentzen, Anne ^a   Gürlevik, Engin ^b   Yuan, Qinggong ^a,b   Steinmann, Eike ^a   Ott, Michael ^a,b   Staeheli, Peter ^c   Schmid Burgk, Jonathan ^d   Schmidt, Tobias ^d   Hornung, Veit ^d   Kuehnel, Florian ^b   Pietschmann, Thomas ^a  

^a INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; INTERFERON; INTERFERON RECEPTOR; INTERFERON TYPE III; MITOCHONDRIAL ANTIVIRAL SIGNALING PROTEIN; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; UNCLASSIFIED DRUG; IPS-1 PROTEIN, MOUSE; NS3 PROTEIN, HEPATITIS C VIRUS; NS4 PROTEIN, HEPATITIS C VIRUS; SIGNAL TRANSDUCING ADAPTOR PROTEIN; VIRUS PROTEIN; VISA PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; INNATE IMMUNITY; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS; REPLICON; SIGNAL TRANSDUCTION; VIRUS REPLICATION; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL LINE; HEPACIVIRUS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; VIROLOGY;

HEPATITIS C VIRUS; MURINAE; MUS; PAN;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CELL LINE; HEPACIVIRUS; HEPATOCYTES; HOST-PATHOGEN INTERACTIONS; HUMANS; INTERFERONS; MICE, INBRED BALB C; MICE, INBRED C57BL; VIRAL NONSTRUCTURAL PROTEINS; VIRUS REPLICATION;

EID: 84924787171     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.03129-14     Document Type: Article

References (36)

1. Maasoumy B, Wedemeyer H. 2012. Natural history of acute and chronic hepatitis C. Best Pract Res Clin Gastroenterol 26:401-412. http://dx.doi.org/10.1016/j.bpg.2012.09.009.
2. Tse MT. 2013. All-oral HCV therapies near approval. Nat Rev Drug Discov 12:409-411. http://dx.doi.org/10.1038/nrd4036.
3. Thomas DL. 2013. Global control of hepatitis C: where challenge meets opportunity. Nat Med 19:850-858. http://dx.doi.org/10.1038/nm.3184.
4. Ploss A, Evans MJ, Gaysinskaya VA, Panis M, You H, de Jong YP, Rice CM. 2009. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells. Nature 457:882-886. http://dx.doi.org/10.1038/nature07684.
5. Dorner M, Horwitz JA, Robbins JB, Barry WT, Feng Q, Mu K, Jones CT, Schoggins JW, Catanese MT, Burton DR, Law M, Rice CM, Ploss A. 2011. A genetically humanized mouse model for hepatitis C virus infection. Nature 474:208-211. http://dx.doi.org/10.1038/nature10168.
6. Bitzegeio J, Bankwitz D, Hueging K, Haid S, Brohm C, Zeisel MB, Herrmann E, Iken M, Ott M, Baumert TF, Pietschmann T. 2010. Adaptation of hepatitisCvirus to mouse CD81 permits infection of mouse cells in the absence of human entry factors. PLoS Pathog 6:e1000978. http://dx.doi.org/10.1371/journal.ppat.1000978.
7. Chang KS, Cai Z, Zhang C, Sen GC, Williams BR, Luo G. 2006. Replication of hepatitis C virus (HCV) RNA in mouse embryonic fibroblasts: protein kinase R (PKR)-dependent and PKR-independent mechanisms for controlling HCV RNA replication and mediating interferon activities. J Virol 80:7364-7374. http://dx.doi.org/10.1128/JVI.00586-06.
8. Lin LT, Noyce RS, Pham TN, Wilson JA, Sisson GR, Michalak TI, Mossman KL, Richardson CD. 2010. Replication of subgenomic hepatitis C virus replicons in mouse fibroblasts is facilitated by deletion of interferon regulatory factor 3 and expression of liver-specific microRNA 122. J Virol 84:9170-9180. http://dx.doi.org/10.1128/JVI.00559-10.
9. Frentzen A, Anggakusuma, Gurlevik E, Hueging K, Knocke S, Ginkel C, Brown RJ, Heim M, Dill MT, Kroger A, Kalinke U, Kaderali L, Kuehnel F, Pietschmann T. 2014. Cell entry, efficient RNA replication, and production of infectious hepatitis C virus progeny in mouse liver-derived cells. Hepatology 59:78-88. http://dx.doi.org/10.1002/hep.26626.
10. Dorner M, Horwitz JA, Donovan BM, Labitt RN, Budell WC, Friling T, Vogt A, Catanese MT, Satoh T, Kawai T, Akira S, Law M, Rice CM, Ploss A. 2013. Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature 501:237-241. http://dx.doi.org/10.1038/nature12427.
11. Li K, Foy E, Ferreon JC, Nakamura M, Ferreon AC, Ikeda M, Ray SC, Gale M, Jr, Lemon SM. 2005. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci USA 102:2992-2997. http://dx.doi.org/10.1073/pnas.0408824102.
12. Meylan E, Curran J, Hofmann K, Moradpour D, Binder M, Bartenschlager R, Tschopp J. 2005. Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. Nature 437:1167-1172. http://dx.doi.org/10.1038/nature04193.
13. Marukian S, Andrus L, Sheahan TP, Jones CT, Charles ED, Ploss A, Rice CM, Dustin LB. 2011. Hepatitis C virus induces interferon-lambda and interferon-stimulated genes in primary liver cultures. Hepatology 54: 1913-1923. http://dx.doi.org/10.1002/hep.24580.
14. Park H, Serti E, Eke O, Muchmore B, Prokunina-Olsson L, Capone S, Folgori A, Rehermann B. 2012. IL-29 is the dominant type III interferon produced by hepatocytes during acute hepatitis C virus infection. Hepatology 56:2060-2070. http://dx.doi.org/10.1002/hep.25897.
15. Sheahan T, Imanaka N, Marukian S, Dorner M, Liu P, Ploss A, Rice CM. 2014. Interferon lambda alleles predict innate antiviral immune responses and hepatitis C virus permissiveness. Cell Host Microbe 15:190-202. http://dx.doi.org/10.1016/j.chom.2014.01.007.
16. Thomas E, Gonzalez VD, Li Q, Modi AA, Chen W, Noureddin M, Rotman Y, Liang TJ. 2012. HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology 142:978-988. http://dx.doi.org/10.1053/j.gastro.2011.12.055.
17. Metz P, Reuter A, Bender S, Bartenschlager R. 2013. Interferonstimulated genes and their role in controlling hepatitis C virus. J Hepatol 59:1331-1341. http://dx.doi.org/10.1016/j.jhep.2013.07.033.
18. Schoggins JW. 2014. Interferon-stimulated genes: roles in viral pathogenesis. Curr Opin Virol 6:40-46. http://dx.doi.org/10.1016/j.coviro.2014.03.006.
19. Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, Rice CM. 2011. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472:481-485. http://dx.doi.org/10.1038/nature09907.
20. Cooper J, Fields JK. 1988. A hospital wellness program: where challenge meets opportunity. Home Healthc Nurse 6:10-16.
21. Rothe M, Rittelmeyer I, Iken M, Rudrich U, Schambach A, Glage S, Manns MP, Baum C, Bock M, Ott M, Modlich U. 2012. Epidermal growth factor improves lentivirus vector gene transfer into primary mouse hepatocytes. Gene Ther 19:425-434. http://dx.doi.org/10.1038/gt.2011.117.
22. Yuan Q, Loya K, Rani B, Mobus S, Balakrishnan A, Lamle J, Cathomen T, Vogel A, Manns MP, Ott M, Cantz T, Sharma AD. 2013. MicroRNA-221 overexpression accelerates hepatocyte proliferation during liver regeneration. Hepatology 57:299-310. http://dx.doi.org/10.1002/hep.25984.
23. Anggakusuma A, Colpitts CC, Schang LM, Rachmawati H, Frentzen A, Pfaender S, Behrendt P, Brown RJ, Bankwitz D, Steinmann J, Ott M, Meuleman P, Rice CM, Ploss A, Pietschmann T, Steinmann E. 2014. Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. Gut 63:1137-1149. http://dx.doi.org/10.1136/gutjnl-2012-304299.
24. Narbus CM, Israelow B, Sourisseau M, Michta ML, Hopcraft SE, Zeiner GM, Evans MJ. 2011. HepG2 cells expressing microRNA miR-122 support the entire hepatitis C virus life cycle. J Virol 85:12087-12092. http://dx.doi.org/10.1128/JVI.05843-11.
25. Yan N, Regalado-Magdos AD, Stiggelbout B, Lee-Kirsch MA, Lieber-man J. 2010. The cytosolic exonuclease TREX1 inhibits the innate immune response to human immunodeficiency virus type 1. Nat Immunol 11:1005-1013. http://dx.doi.org/10.1038/ni.1941.
26. Sommereyns C, Paul S, Staeheli P, Michiels T. 2008. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 4:e1000017. http://dx.doi.org/10.1371/journal.ppat.1000017.
27. Bossaller L, Rathinam VA, Bonegio R, Chiang PI, Busto P, Wespiser AR, Caffrey DR, Li Q Z, Mohan C, Fitzgerald KA, Latz E, Marshak-Rothstein A. 2013. Overexpression of membrane-bound fas ligand (CD95L) exacerbates autoimmune disease and renal pathology in pristane-induced lupus. J Immunol 191:2104-2114. http://dx.doi.org/10.4049/jimmunol.1300341.
28. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. 2006. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 80:4501-4509. http://dx.doi.org/10.1128/JVI.80.9.4501-4509.2006.
29. Fensterl V, White CL, Yamashita M, Sen GC. 2008. Novel characteristics of the function and induction of murine p56 family proteins. J Virol 82: 11045-11053. http://dx.doi.org/10.1128/JVI.01593-08.
30. Kawai T, Takahashi K, Sato S, Coban C, Kumar H, Kato H, Ishii KJ, Takeuchi O, Akira S. 2005. IPS-1, an adaptor triggering RIG-I-and Mda5-mediated type I interferon induction. Nat Immunol 6:981-988. http://dx.doi.org/10.1038/ni1243.
31. Ahlen G, Derk E, Weiland M, Jiao J, Rahbin N, Aleman S, Peterson DL, Pokrovskaja K, Grander D, Frelin L, Sallberg M. 2009. Cleavage of the IPS-1/Cardif/MAVS/VISA does not inhibit T cell-mediated elimination of hepatitis C virus non-structural 3/4A-expressing hepatocytes. Gut 58: 560-569. http://dx.doi.org/10.1136/gut.2007.147264.
32. Vogt A, Scull MA, Friling T, Horwitz JA, Donovan BM, Dorner M, Gerold G, Labitt RN, Rice CM, Ploss A. 2013. Recapitulation of the hepatitis C virus life-cycle in engineered murine cell lines. Virology 444: 1-11. http://dx.doi.org/10.1016/j.virol.2013.05.036.
33. Abe T, Kaname Y, Hamamoto I, Tsuda Y, Wen X, Taguwa S, Moriishi K, Takeuchi O, Kawai T, Kanto T, Hayashi N, Akira S, Matsuura Y. 2007. Hepatitis C virus nonstructural protein 5A modulates the Toll-like receptor-MyD88-dependent signaling pathway in macrophage cell lines. J Virol 81:8953-8966. http://dx.doi.org/10.1128/JVI.00649-07.
34. Lazear HM, Lancaster A, Wilkins C, Suthar MS, Huang A, Vick SC, Clepper L, Thackray L, Brassil MM, Virgin HW, Nikolich-Zugich J, Moses AV, Gale M, Jr, Fruh K, Diamond MS. 2013. IRF-3, IRF-5, and IRF-7 coordinately regulate the type I IFN response in myeloid dendritic cells downstream of MAVS signaling. PLoS Pathog 9:e1003118. http://dx.doi.org/10.1371/journal.ppat.1003118.
35. Hermant P, Demarez C, Mahlakoiv T, Staeheli P, Meuleman P, Michiels T. 2014. Human but not mouse hepatocytes respond to interferon-lambda in vivo. PLoS One 9:e87906. http://dx.doi.org/10.1371/journal.pone.0087906.
36. Ding S, Khoury-Hanold W, Iwasaki A, Robek MD. 2014. Epigenetic reprogramming of the type III interferon response potentiates antiviral activity and suppresses tumor growth. PLoS Biol 12:e1001758. http://dx.doi.org/10.1371/journal.pbio.1001758.